Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 7:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2185–2208 of 6,923 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Stimulation Clear all

Conditions: Cushing's Disease, Pituitary Adenoma
Interventions: Desmopressin acetate; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 8 Years to 99 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy
Interventions: Modified Release rhTSH; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Miami, Florida

Conditions: B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia
Interventions: Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Collection, Computed Tomography, Cyclophosphamide, Doxorubicin, Etoposide, Filgrastim, Pegfilgrastim, Positron Emission Tomography, Prednisone, Rituximab, Vincristine; Drug · Procedure · Biological
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: ACL
Interventions: NMES, Vibration; Device
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 40 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Mild Cognitive Impairment, Amnestic Mild Cognitive Impairment - aMCI
Interventions: NeuroElectric StarStim, Sham Treatment; Device
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 55 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Knee Osteoarthritis
Interventions: Self Transcranial Direct Current Stimulation (tDCS), mindfulness-based meditation, Sham Self Transcranial Direct Current Stimulation (tDCS), sham meditation; Device · Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 50 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Opioid Use Disorder
Interventions: active tDCS, sham tDCS; Device
Lead sponsor: Butler Hospital; Other
Eligibility: 21 Years to 60 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Infertility, Female
Interventions: Clomiphene Citrate; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Pasadena, California

Conditions: HIV Infections, Cytopenias
Interventions: Epoetin alfa; Drug
Lead sponsor: Ortho Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Raritan, New Jersey

Conditions: Cerebrovascular Accident
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: PostTraumatic Stress Disorder
Interventions: GammaCore/electroCore non-invasive VNS device, Sham gammaCore/electroCore, O-15 water; Device · Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Epilepsy
Interventions: The Magstim Rapid2,; Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 12 Years to 60 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Androgenic Alopecia, Female Pattern Hair Loss, Hair Loss
Interventions: Scalp Stimulating Serum, Red Light Hair Growth Cap, Placebo scalp-stimulating serum; Other · Device
Lead sponsor: K. Kay Durairaj, MD, FACS, A Medical Corporation; Other
Eligibility: 35 Years to 55 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Overactive Bladder
Interventions: StimRouter; Device
Lead sponsor: Bioness Inc; Industry
Eligibility: 22 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 15
States / cities: Tucson, Arizona • Irvine, California • Los Angeles, California + 12 more

Conditions: Parent-Child Relations, Maternal Behavior, Infant Behavior
Interventions: ATVV, Attention control; Behavioral
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older · Female only
Enrollment: 262 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Tucson, Arizona

Conditions: Schizophrenia
Interventions: transcranial Direct Current Stimulation (tDCS), Sham tDCS; Device
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 55 Years
Enrollment: 89 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 2
States / cities: New York, New York • Orangeburg, New York

Conditions: Aging
Interventions: Mindfulness-Based Stress Reduction (MBSR), Lifestyle Education (LifeEd); Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 65 Years to 85 Years
Enrollment: 173 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Diabetes Mellitus, Type 1
Interventions: Anti-Thymocyte Globulin (ATG), Granulocyte colony stimulating factor (GCSF), Placebo (for ATG), Placebo (for GCSF); Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 12 Years to 45 Years
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 13
States / cities: San Francisco, California • Stanford, California • Aurora, Colorado + 10 more

Conditions: HIV Associated Polyneuropathy
Interventions: Transcutaneous Auricular Vagus Nerve Stimulation (AVNS); Device
Lead sponsor: University of Miami; Other
Eligibility: 50 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Memory Disorders
Interventions: Neurocognitive Tasks, Ripple Neuromed Summit System; Behavioral · Device
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: High Risk Neuroblastoma
Interventions: Aldesleukin, Diagnostic Laboratory Biomarker Analysis, Dinutuximab, Isotretinoin, Sargramostim; Biological · Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2021
U.S. locations: 32
States / cities: Loma Linda, California • Los Angeles, California • Orange, California + 25 more

Conditions: Motor Memory
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Palsy Supranuclear, Supranuclear Palsy, Progressive
Interventions: Repetitive transcranial magnetic stimulation (rTMS); Device
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 40 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Anemia
Interventions: Epoetin alfa, methoxy polyethylene glycol-epoetin beta [Mircera]; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 29
States / cities: Birmingham, Alabama • Bakersfield, California • Chula Vista, California + 26 more

Search by objective public record fields.

DDAVP for Pituitary Adenoma

Study Comparing Thyrogen Versus a Modified Release of Recombinant Human Thyroid Stimulating Hormone

Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

Interventions to Enhance Quadriceps Output After ACLR

Cognitive Outcomes of Brain Stimulation As a Later-in-Life Treatment

Self Transcranial Direct Current Stimulation and Mindfulness-based Meditation for Pain in Older Adults With Knee Osteoarthritis

tDCS to Decrease Opioid Relapse (UH3)

Evaluation of a Long Versus Short Clomid Protocol for Controlled Ovarian Stimulation

A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy

Hand Exercise and Upper Arm Anesthesia to Improvements Hand Function in Chronic Stroke Patients

Closed Loop Vagal Nerve Stimulation for Patients With Posttraumatic Stress Disorder

Presurgical Motor Mapping With Transcranial Magnetic Stimulation (TMS)

Dual Modality Treatment of Androgenic Alopecia With KeraFactor® Solution and Revian® LED Light Therapy

Overactive Bladder Treatment Using StimRouter Neuromodulation System: A Prospective Randomized Trial

A Randomized Controlled Trial to Improve Mother-Infant Synchrony Among Women With Childhood Adversity

TDCS for Auditory Hallucinations in Schizophrenia

Mind-body Interventions for Healthy Aging

ATG-GCSF in New Onset Type 1 Diabetes

Auricular Vagus Nerve Stimulation Mechanisms for HIV-Associated Peripheral Neuropathy

Neural Basis of Human Working Memory

Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma

Enhancing Motor Task Training by Action Observation Watching Others Perform the Task

Transcranial Magnetic Stimulation in Progressive Supranuclear Palsy

A Study of Subcutaneous Mircera for the Treatment of Anemia in Peritoneal Dialysis Patients.